Immunocytochemical analysis of tumor cells in pre- and post-culture peripheral blood progenitor cell collections from breast cancer patients

Exp Hematol. 1995 Dec;23(14):1478-83.


We examined peripheral blood progenitor cell (PBPC) collections and CD(34+)-selected fractions cultured in PIXY321, a fusion protein comprising analog interleukin-3 (IL-3) and granulocyte-macrophage colony-stimulating factor (GM-CSF) domains, for the presence of contaminating tumor cells from 14 patients with advanced-stage breast cancer. Five of the 14 (36%) pre-culture PBPC specimens contained immunocyto-chemically (ICC)-detectable tumor cells using two different cocktails of monoclonal antibodies (mAbs). After 10 days in culture with PIXY321, the CD(34+)-selected fractions showed a median 23.6-fold expansion of hematopoietic cells. No ICC-positive tumor cells were detected in any post-culture specimens. We conclude that in vitro expansion of CD(34+)-selected PBPCs with PIXY321 can expand hematopoietic cell populations apparently without risk of expanding contaminating breast cancer cell populations.

MeSH terms

  • Antibodies, Monoclonal
  • Antigens, CD34 / analysis
  • Breast Neoplasms / pathology*
  • Cell Separation
  • Cell Survival
  • Culture Media
  • Female
  • Flow Cytometry
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Immunohistochemistry*
  • Interleukin-3 / pharmacology
  • Recombinant Fusion Proteins / pharmacology
  • Tumor Cells, Cultured


  • Antibodies, Monoclonal
  • Antigens, CD34
  • Culture Media
  • Interleukin-3
  • Recombinant Fusion Proteins
  • Granulocyte-Macrophage Colony-Stimulating Factor